Cancer is a disease of old age; however, most studies usually included minority of patients fit elderly. The purpose is to investigate the clinical characteristics and genetic information of patients with thoracic tumors who are 80 years old or older compared to those under 80 years old. The Thoracic Tumor Registry (TTR) is a Spanish observational, prospective cohort study that included patients diagnosed with thoracic tumors. Data were collected from medical records related to sociodemographic, epidemiological, clinical, molecular/genetic, and treatment outcome variables. The total number of patients, recruited from August 2016 to April 2023, was 26.193 (93,1 % were younger than 80 years and 6,9 % were 80 years or older). In the group of older patients: the male ratio increased (72,9 % vs. 80 %); the number of elderly people who had never smoked or were ex-smokers increased (9,9 % vs. 21,1 % and 44,8 % vs. 61,3 %, respectively) and the number of current smokers decreased (43,3 % vs. 17,5 %); had higher ECOG performance status at diagnosis (for ECOG ≥ 2, 15 % vs. 32,9 %), and there were more patients with previous cancer (17,3 % vs. 28 %). The proportion of men is higher than that of women (73 % vs. 27 % in <80 years and 80 % vs. 20 % in ≥80 years). The proportion of older patients with targeted mutations is higher. So, at least at diagnosis, it should be proceeded in a standard way. Then, when it comes to treatment, comorbidities and patient’s baseline situation should be considered.

中文翻译：

---

描述 80 岁以下和 80 岁以上胸部肿瘤患者群体之间的差异：SLCG 胸部肿瘤登记处的数据分析

癌症是一种老年疾病；然而，大多数研究通常包括少数适合老年人的患者。目的是调查80岁以上胸部肿瘤患者与80岁以下患者的临床特征和遗传信息。胸部肿瘤登记处 (TTR) 是一项西班牙观察性前瞻性队列研究，其中包括诊断患有胸部肿瘤的患者。数据收集自与社会人口学、流行病学、临床、分子/遗传和治疗结果变量相关的医疗记录。 2016 年 8 月至 2023 年 4 月期间招募的患者总数为 26.193 名（93.1% 年龄小于 80 岁，6.9% 80 岁或以上）。在老年患者组中：男性比例增加（72.9% vs. 80%）；从未吸烟或戒烟的老年人数量增加（分别为 9.9% vs. 21.1% 和 44.8% vs. 61.3%），而当前吸烟者数量减少（43, 3% 对比 17.5%)；诊断时具有较高的 ECOG 表现状态（对于 ECOG ≥ 2，为 15 % vs. 32.9 %），并且有更多患者既往患有癌症（17.3 % vs. 28 %）。男性比例高于女性（<80 岁为 73% vs. 27%，≥80 岁为 80% vs. 20%）。老年患者携带靶向突变的比例更高。所以，至少在诊断时，应该以标准的方式进行。然后，在治疗时，应考虑合并症和患者的基线情况。